Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,619.79
(
1.74%
)
US TECH 100
23,771.60
(
2.10%
)
Dow Jones
46,515.94
(
2.06%
)
Brent Oil
96.64
(
-10.63%
)
Bitcoin
70,782.42
(
4.35%
)
News Focus
News Focus
Post# of 257269
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

jq1234

Send PM Follow Ignore
Followers 69
Posts 4516
Boards Moderated 0
Alias Born 12/13/2009

jq1234

Re: biomaven0 post# 131169

Tuesday, 11/15/2011 11:30:33 PM

Tuesday, November 15, 2011 11:30:33 PM

Post# of 257269
I definitely agree MDV3100's theoretical advantage over Zytiga. However, I do think market gives fair valuation to MDVN currently - need to see full data.

In addition, Charles Sawyer founded Aragon two years ago to develope ARN509, similar but supposely better version of MDV3100.

http://www.aragonpharm.com/programs/arn509.htm
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today